A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vaccitech PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 16,037 shares of VACC stock, worth $54,686. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,037
Holding current value
$54,686
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
N/A
16,037 New
16,037 $54,000
Q2 2023

Aug 14, 2023

BUY
$2.06 - $2.51 $30,646 - $37,341
14,877 New
14,877 $30,000
Q4 2022

Feb 14, 2023

BUY
$2.1 - $2.68 $36,504 - $46,586
17,383 New
17,383 $40,000

Others Institutions Holding VACC

About Vaccitech plc


  • Ticker VACC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,216,200
  • Market Cap $127M
  • Description
  • Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B...
More about VACC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.